Cullinan Therapeutics (CGEM) Change in Accured Expenses: 2020-2024
Historic Change in Accured Expenses for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to $2.9 million.
- Cullinan Therapeutics' Change in Accured Expenses rose 219.77% to $5.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $10.1 million, marking a year-over-year increase of 17.82%. This contributed to the annual value of $2.9 million for FY2024, which is 71.21% down from last year.
- As of FY2024, Cullinan Therapeutics' Change in Accured Expenses stood at $2.9 million, which was down 71.21% from $10.1 million recorded in FY2023.
- Over the past 5 years, Cullinan Therapeutics' Change in Accured Expenses peaked at $10.1 million during FY2023, and registered a low of $1.8 million during FY2020.
- Moreover, its 3-year median value for Change in Accured Expenses was $8.5 million (2022), whereas its average is $7.2 million.
- Per our database at Business Quant, Cullinan Therapeutics' Change in Accured Expenses soared by 160.74% in 2021 and then slumped by 71.21% in 2024.
- Over the past 5 years, Cullinan Therapeutics' Change in Accured Expenses (Yearly) stood at $1.8 million in 2020, then soared by 160.74% to $4.6 million in 2021, then surged by 87.00% to $8.5 million in 2022, then climbed by 17.82% to $10.1 million in 2023, then crashed by 71.21% to $2.9 million in 2024.